S. 2285: Uterine Cancer Study Act of 2025

This bill, known as the Uterine Cancer Study Act of 2025, proposes to direct the Secretary of Health and Human Services to conduct a study examining the relationship between chemical hair straighteners and uterine cancer, focusing particularly on the increased rates of this type of cancer among women of color.

Key Components of the Bill

• Study Coordination: The Secretary of Health and Human Services will work alongside the Commissioner of Food and Drugs and the Director of the National Institutes of Health to carry out the study.
• Review of Existing Research: The study will review significant findings and recommendations from prior research concerning the relationship between hair straighteners and uterine cancer.
• Diverse Impact Consideration: It will take into account the potential impact on women and individuals at risk of uterine cancer from various racial and ethnic backgrounds.
• Disaggregation of Results: The findings will be categorized based on whether the hair straighteners contain dyes, bleach, highlights, or are used in perms.
• FDA Testing Requirements: The study will assess whether the Food and Drug Administration (FDA) should impose additional testing requirements on hair straightener manufacturers to ensure product safety.

Timeline and Reporting

• Methodology Submission: The Secretary must submit a description of the study's methodology to two Senate and House Committees within 45 days of the bill’s enactment.
• Study Commencement: The study is to begin within 180 days following the enactment of the bill.
• Final Report: The Secretary will complete the study and submit a report detailing the results to the same committees within two years of the bill’s enactment.

Definitions

• Hair Straightener: Refers specifically to chemical hair straighteners.
• Secretary: Refers to the Secretary of Health and Human Services.

Relevant Companies

None found